The Global Electronic Clinical Outcome Assessment Solution Market (eCOA) size is expected to reach $2.4 billion by 2026, rising at a market growth of 19% CAGR during the forecast period. Electronic clinical outcome assessment (eCOA) refers to a system that is capable of measuring mental state, patient symptom, and the prognosis of a disease. Some major components of eCOA platforms are electronic diaries and electronic Patient Reported Outcomes (ePRO). These components act as support systems for ePRO. In every type of application of clinical outcome assessment systems, the compliance rates are very high, which facilitates the research procedures.
Over the years, electronic clinical outcome assessment has proved to be very effective and cost-efficient. There is a rapid increment of investment from the pharmaceutical industry on clinical trials, while the demand & development of clinical data management is constantly growing. The market growth is expected to be affected positively by the development of cloud computing in the pharmaceutical industry. On the other hand, the eCOA is associated with a high initial cost of installation, which is a pressing concern for sponsors of clinical trials, & mid-scale pharmaceutical manufacturers. This factor is likely to slow down the growth rate of the global electronic clinical outcome assessment solution market in the next few years.
The adoption & demand for eCOA solutions would be fuelled due to the complexity of healthcare information management. Using these systems, healthcare facilities can expect accurate & timely delivery of health information & decrease the pressure of patients who are undergoing clinical trials. The demand for R&D to create innovative treatments & drugs is increasing with the massive growth of the healthcare industry. The increasing number of research studies is creating a need for a unified data capture system. Therefore, all the mentioned aspects would drive the product demand during the forecast period.
Delivery Mode Outlook
Based on Delivery Mode, the market is segmented into Web-hosted eCOA, Cloud-based eCOA, and Licensed enterprises eCOA. The web-hosted eCOA solutions segment garnered the maximum revenue share in 2019. This high revenue share is credited to the numerous advantages & applications of the segment. Web-based services provide some major benefits including remote access to the health information of the patient & information sharing in order to restrict the potential risk of data misuse or resolve the issues at a critical point of the study.
End Use Outlook
Based on End Use, the market is segmented into Contract Research Organizations (CROs), Hospitals, Academic Institutes, Pharma & Biotech Companies and Medical Device Manufacturers. Contract Research Organizations (CROs) procured the major revenue share in 2019. Moreover, this segment is anticipated to observe a high growth rate in the next few years due to the increasing demand from the pharma giants. The CROs segment is expected to show bright growth as this often puts high pressure on pharma companies to bring down the overall cost of clinical development studies.
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 2019, North America emerged as a dominant region in the global market. The existence of medical device manufacturers, technologically developed research centers, universities, and hospitals along with the superior healthcare infrastructure would boost the initiatives regarding the new drug development in the next few years. In North America, the U.S. procured the maximum revenue share of the market. This is attributed to the massive adoption of healthcare analytics services. Governments as well as nonprofit organizations are undertaking various initiatives regarding the adoption of eClinical platforms, which further boosts the demand for these products.
The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; Oracle Corporation and IBM Corporation are the forerunners in the Electronic Clinical Outcome Assessment Solution Market (ECOA). Companies such as Signant Health, ERT Clinical, Parexel International Corporation, IQVIA Holdings, Inc. are some of the key innovators in the market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Oracle Corporation, Dassault Systemes SE, IQVIA Holdings, Inc., Parexel International Corporation (Pamplona Capital Management), IBM Corporation (Merge Healthcare), Signant Health, ERT Clinical, eClinical Solutions LLC, Castor EDC and Anju Software, Inc. (OmniComm Systems).
Nov-2020: Medidata came into collaboration with Oxford University Innovation’s Clinical Outcomes Team (OUI). In this collaboration, the companies aimed to initiate actively integrating OUI’s stable clinical outcome assessments (COAs) into Medidata’s electronic COA (eCOA) Global Library. The collaboration also helped in boosting clinical study start-up, support quality enhancements, and propel study management efficiency.
Oct-2020: Signant Health partnered with Aural Analytics, Inc., an industry-leading speech neuroscience and speech analytics technology company. The partnership aimed to integrate its A2E mobile application SDK and Web API over the Signant Health’s Rater Station and TrialMax training, data quality overviewing, and eCOA solutions.
Oct-2020: Signant Health came into partnership with Science 37, the leader in decentralized clinical trials. The partnership aimed to strengthen the capabilities for decentralized or virtual central nervous system (CNS) clinical research. The companies brought together Science 37’s best-in-class decentralized trial capability and Signant’s proven data collection technologies, providing sponsors and sites digitally enabled solutions for conducting CNS studies.
Sep-2020: Castor entered into a partnership with Click Therapeutics, a leader in the field of digital therapeutics. Under this partnership, the companies focused on providing solutions for conducting fully remote clinical trials. Castor delivered Click with solutions for digital enrollment, remote data capture (EDC and eCOA), and electronic consent (eConsent).
Jul-2020: ERT came into partnership with Cogstate, the leading neuroscience technology company. The partnership focused on expanding ERT’s industry-leading electronic Clinical Outcome Assessment (eCOA) solution with digital cognitive endpoint measurement to enhance safety and value assessment in clinical trials that include the capabilities for at-home testing.
May-2020: Parexel Informatics, a division of Parexel collaborated with Microsoft Azure. Under this collaboration, Parexel introduced the #KeepingPatientsFirst integrated Real-World Evidence (RWE) research platform for gathering critical evidence and boosting patient and physician access to insights on the treatment and outcomes in COVID-19.
Sep-2019: Medidata entered into a collaboration with Mapi Research Trust, curator of Clinical Outcomes Assessments (COA). Under this collaboration, the companies announced a new critical mission to make a digital, global library of pre-configured and pre-approved eCOA (clinical outcomes assessment) questionnaires. This collaboration made reusable versions of MRT distributed questionnaires in Medidata Rave eCOA, gathering COA data from hundreds of studies every year on the Medidata platform.
Sep-2019: Signant Health collaborated with the Shanghai Mental Health Centre (SMHC), a leading organization on mental health prevention planning. This collaboration helped Signant to offer electronic informed consent for a significant neuroscience study by SMHC.
Acquisition and Mergers:
Dec-2020: ERT announced the merger of Bioclinica, a technological and scientific leader in clinical imaging and ERT. Together the companies created a leading partner to global pharmaceutical and biotechnology companies, offering best-in-class technology, and digital innovation scientific & therapeutic expertise and a strong focus on customer service. Under this merger, Bioclinica’s expertise in imaging was integrated with ERT’s expertise in eCOA, respiratory, wearables, and cardiac safety.
Nov-2020: Signant Health took over VirTrial, a leading provider of software solutions. In this acquisition, Signant Health added the capabilities of VirTrial to expand its software stack to further digitally improved trial sites and provide sponsors superior evidence generation around decentralized, traditional, and hybrid trial models. Signant Health’s complete suite of technology and clinical expertise, integrated with VirTrial’s telemedicine platform, better support sites as sponsors boost their trial strategies to digitalize methods during COVID-19 and after that too.
Feb-2017: ERT took over Exco InTouch, data capture and digital health Solutions Company. The acquisition aimed to make ERT a one-stop-shop to offer the biopharmaceutical industry the most enhanced and complete choice for electronic clinical outcome assessments (Ecoa), digital health, and patient engagement.
Product Launches and Product Expansions:
Sep-2020: Signant Health launched eCOA Explained, a new Master Class web series. This series was developed to boost the understanding and skills of clinical operations professionals who have an interest in electronic clinical outcome assessments (eCOA). The educational and complimentary class introduced with three courses and 16 on-demand lessons developed for each level of eCOA experience, as trained by 13 clinical research science and technology experts.
Jun-2019: IQVIA launched the Patient-Centered Endpoints (PCE) solution. The solution is an advanced science and technology-enabled approach that collects quantified evidence of patients’ experiences at the time of clinical trials and real-world studies. This technology allows trial sponsors to understand better the patients’ experiences on different therapies, diminish study implementation timelines, and improved data transparency.
Scope of the Study
Market Segments covered in the Report:
By Delivery Mode
• Web-hosted eCOA
• Cloud-based eCOA
• Licensed enterprises eCOA
By End Use
• Contract Research Organizations (CROs)
• Academic Institutes
• Pharma & Biotech Companies
• Medical Device Manufacturers
• North America
o Rest of North America
o Rest of Europe
• Asia Pacific
o South Korea
o Rest of Asia Pacific
o Saudi Arabia
o South Africa
o Rest of LAMEA
• Oracle Corporation
• Dassault Systemes SE
• IQVIA Holdings, Inc.
• Parexel International Corporation (Pamplona Capital Management)
• IBM Corporation (Merge Healthcare)
• Signant Health
• ERT Clinical
• eClinical Solutions LLC
• Castor EDC
• Anju Software, Inc. (OmniComm Systems)
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free
Our reports have been used by over 10K customers, including:
384 pages •
By Global Industry Analysts
• Apr 2021
- The global Label-Free Detection market is projected to reach US$1.3 billion by 2025, driven by growing drug R&D, rising competitive pressure to reduce cost of drug development and the resulting need for cost-effective and efficient screening technologies. Traditional label-based assays are beset with drawbacks...
The North America Electronic Clinical Outcome Assessment Solution Market (eCOA) would witness market growth of 18.3% CAGR during the forecast period (2020-2026). With an aim to collect patient data during clinical trials & observation studies, there is high utilization of eCOAs, including electronic ClinROs (Clinician Reported Outcomes),...
The Europe Electronic Clinical Outcome Assessment Solution Market (eCOA) would witness market growth of 18.6% CAGR during the forecast period (2020-2026). Electronic-based services for data capturing & analyzing effectively beat every limitation of paper-based procedures, with a surge in patient compliance. With the help of these solutions,...
The Asia Pacific Electronic Clinical Outcome Assessment Solution Market (eCOA)would witness market growth of 20.6% CAGR during the forecast period (2020-2026). With an aim to gather patient data in a clinical trial, an eCOA solution is utilized. The global electronic clinical outcome assessment (eCOA) solutions market is anticipated...
The Latin America, Middle East and Africa Electronic Clinical Outcome Assessment Solution Market (ECOA) would witness market growth of 20.2% CAGR during the forecast period (2020-2026). A Patient’s mental state, the prognosis of a disease, illness conditions, and the role of a patient in that situation can be evaluated with the help...
Readers of one of the analyst’s media partners were invited to participate in an online survey in September 2020 that centered on the state of their laboratories in 2020 and their expectations for 2021.The analyst has conducted similar studies among the same targeted respondents since 2012.
Where applicable, the study presents year-over-year...
The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021 report. The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option...
The global custom antibody market is projected to reach USD 652 million by 2026 from USD 393 million in 2021, at a CAGR of 10.6% during the forecast period.The increasing demand for protein therapeutics is expected to drive the custom antibody market in the coming years. On the other hand, the need for significant capital investments and long...
Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 126.96.36.199) - Drugs in Development, 2021 Summary Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 188.8.131.52) - Phenylalanine 4 hydroxylase or Phenylalanine hydroxylase (PAH) is an enzyme that catalyzes the hydroxylation of...
Health Provider Density
Use Of Prescription Drugs
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.